肺癌放化疗后心脏FDG-PET代谢变化评估
结果显示心脏SUVmean每10 Gy平均增加1.7%,且SUVmean变化是多因素分析中总生存的显著预测因子(HR 0.541,95%CI 0.312-0.937)。
要点
- 心脏SUVmean随心脏剂量增加而升高,平均每10 Gy增加1.7%。
- 治疗前后SUVmean变化可预测总生存(HR 0.541,95%CI 0.312-0.937)。
- 存活者心脏SUVmean平均增加17.2%,死亡者平均降低13.5%(P = .048)。
核心结论
- 治疗前后心脏SUV变化既反映剂量-反应关系,也是总生存的预测因子。
主要发现
- 剂量-反应曲线显示SUV变化随心脏剂量增加而增大,SUVmean平均每10 Gy增加1.7%。
- 中位随访437天(范围201-1131天),多因素分析显示SUVmean变化显著预测总生存,HR 0.541(95%CI 0.312-0.937)。
- 随访时存活者心脏SUVmean平均增加17.2%,死亡者平均降低13.5%(P = .048)。
临床怎么用
- 心脏代谢变化可能作为早期预测临床结局的指标,但需在独立队列中验证。
局限性
- 本研究为假设生成性工作,必须在独立队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Studies have noted a link between radiation dose to the heart and overall survival (OS) for patients with lung cancer treated with chemoradiation. The purpose of this study was to characterize pre- to posttreatment cardiac metabolic changes using fluorodeoxyglucose/positron emission tomography (FDG-PET) images and to evaluate whether changes in cardiac metabolism predict for OS. METHODS AND MATERIALS: Thirty-nine patients enrolled in a functional avoidance prospective study who had undergone pre- and postchemoradiation FDG-PET imaging were evaluated. For each patient, the pretreatment and posttreatment PET/CTs were rigidly registered to the planning CT, dose, and structure set. PET-based metabolic dose-response was assessed by comparing pretreatment to posttreatment mean standardized uptake values (SUVmean) in the heart as a function of dose-bin. OS analysis was performed by comparing SUVmean changes for patients who were alive or had died at last follow-up and by using a multivariate model to assess whether pre- to posttreatment SUVmean changes were a predictor of OS. RESULTS: The dose-response curve revealed increasing changes in SUV as a function of cardiac dose with an average SUVmean increase of 1.7% per 10 Gy. Patients were followed for a median of 437 days (range, 201-1131 days). SUVmean change was significantly predictive of OS on multivariate analysis with a hazard ratio of 0.541 (95% confidence intervals, 0.312-0.937). Patients alive at follow-up had an average increase of 17.2% in cardiac SUVmean while patients that died had an average decrease in SUVmean decrease of 13.5% (P = .048). CONCLUSIONS: Our data demonstrated that posttreatment SUV changes in the heart were significant indicators of dose-response and predictors of OS. The present work is hypothesis generating and must be validated in an independent cohort. If validated, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.
引用
- Vinogradskiy Y, Diot Q, Jones B, et al. Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 31983558. doi:10.1016/j.ijrobp.2019.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。